Pancreatin

Insufficiency of the exocrine function of the pancreas (including in cases of chronic pancreatitis and cystic fibrosis). Chronic inflammatory and degenerative diseases of the stomach, intestines, liver, and gallbladder; conditions following resection or radiation therapy of these organs, accompanied by digestive disorders, flatulence, and diarrhea (as part of combination therapy). To improve digestion in patients with normal gastrointestinal function who have dietary imbalances, as well as in cases of impaired chewing function, prolonged forced immobilization, or a sedentary lifestyle. Preparation for X-ray and ultrasound examinations of the abdominal organs.

Take orally. The dosage, regimen, and duration of treatment are determined on an individual basis, depending on the indications, clinical situation, the patient’s age, and the dosage form used. The average dose for adults is 150,000 IU per day. The duration of treatment can range from a few days (for digestive disorders caused by dietary errors) to several months or even years (when long-term replacement therapy is required).

Use is not recommended during the acute phase of chronic pancreatitis. It may be used during the resolution phase of an acute episode when the diet is being gradually expanded, if there are signs of digestive upset. In cystic fibrosis, the dose should be sufficient to provide the amount of enzymes needed for fat absorption, taking into account the quality and quantity of food consumed. In patients with cystic fibrosis, pancreatin doses exceeding 10,000 IU/kg/day (based on lipase content) are not recommended due to an increased risk of strictures (fibrotic colopathy) in the ileocecal region and the ascending colon. Patients with cystic fibrosis, particularly when taking high doses of pancreatin, may experience hyperuricosuria; therefore, uric acid levels in the urine should be monitored in this patient group. As a precautionary measure, a medical examination is necessary if unusual abdominal discomfort occurs or if there is a change in the nature of symptoms while taking pancreatin, especially at doses exceeding 10,000 IU of lipase per kilogram per day. High levels of lipase in pancreatin increase the likelihood of constipation in children. The dose of pancreatin should be increased gradually in this patient group. Gastrointestinal disturbances may occur in patients who are hypersensitive to pancreatin, or in patients with a history of meconium ileus or bowel resection.

Hypersensitivity to pancreatin; acute pancreatitis; pediatric use—depending on the dosage form.

3 years.